ELP Technology

Christensen et al. 2013. Predicting transition temperature of elastin-like polypeptide fusion proteins. Biomacromolecules.

Kowalczyk et al. 2014. Elastin-like polypeptides as a promising family of genetically-engineered protein based polymers. World Journal of Microbiology and Biotechnology.

McDaniel et al. 2013. A unified model for de novo design of elastin-like polypeptides with tunable inverse transition temperatures. Biomacromolecules.

Vasoactive Intestinal Peptide

Alshafie et al. 2014. VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKCε-dependent manner. American Journal of Physiology – Cell Physiology.

Hamidi et al. 2011. VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension. Respiratory Research.

Henning and Sawmiller 2001. Vasoactive intestinal peptide: cardiovascular effects. Cardiovascular Research.

Koga et al. 2014. Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats. .

McNally et al. 2015. Contemporary cardiac issues in Duchenne Muscular Dystrophy. Circulation.

Said et al. 2007. Moderate Pulmonary Arterial Hypertension in Male Mice Lacking the Vasoactive Intestinal Peptide Gene. .

Szema et al. 2013. VIP gene deletion in mice causes cardiomyopathy associated with upregulation of heart failure genes. PLOS ONE.

PB2452/MEDI2452

Almquist et al. 2016 Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (ticagrelor antidote) by mathematical modeling. CPT Pharmacometrics & Systems Pharmacololgy

Buchanan et al. 2015. Structural and functional characterization of a specific antidote for ticagrelor. Blood.

Erlinge 2015. The first specific antiplatelet antidote. Blood